BioCryst Pharmaceuticals, Inc.
BCRX
$7.97
$0.121.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 159.40M | 163.35M | 145.53M | 131.53M | 117.09M |
| Total Other Revenue | -- | -- | -- | -- | 766.00K |
| Total Revenue | 159.40M | 163.35M | 145.53M | 131.53M | 117.09M |
| Cost of Revenue | 46.79M | 46.18M | 41.84M | 55.57M | 44.29M |
| Gross Profit | 112.61M | 117.17M | 103.70M | 75.96M | 72.79M |
| SG&A Expenses | 83.01M | 87.38M | 82.47M | 80.47M | 65.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.80M | 133.57M | 124.31M | 136.04M | 109.39M |
| Operating Income | 29.59M | 29.79M | 21.23M | -4.51M | 7.69M |
| Income Before Tax | 12.13M | 6.49M | 758.00K | -25.99M | -13.45M |
| Income Tax Expenses | -769.00K | 1.40M | 726.00K | 804.00K | 586.00K |
| Earnings from Continuing Operations | 12.90M | 5.09M | 32.00K | -26.80M | -14.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.90M | 5.09M | 32.00K | -26.80M | -14.03M |
| EBIT | 29.59M | 29.79M | 21.23M | -4.51M | 7.69M |
| EBITDA | 29.93M | 30.12M | 21.56M | -2.43M | 8.00M |
| EPS Basic | 0.06 | 0.02 | 0.00 | -0.13 | -0.07 |
| Normalized Basic EPS | 0.04 | 0.03 | 0.00 | -0.08 | -0.04 |
| EPS Diluted | 0.06 | 0.02 | 0.00 | -0.13 | -0.07 |
| Normalized Diluted EPS | 0.04 | 0.03 | 0.00 | -0.08 | -0.04 |
| Average Basic Shares Outstanding | 210.18M | 209.52M | 208.88M | 207.38M | 206.91M |
| Average Diluted Shares Outstanding | 219.89M | 219.89M | 215.26M | 207.38M | 206.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |